PUMA BIOTECHNOLOGY, INC. (PBYI) Balance Sheet
As of 2026-06-30 (10-Q), PUMA BIOTECHNOLOGY, INC. (PBYI) reported total assets of $192.7M, total liabilities of $54.2M and shareholders' equity of $138.5M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $36.5M. Long-term debt: $0.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
PBYIPUMA BIOTECHNOLOGY, INC.Follow PBYI — free
—
Price chart with a free account
- Market cap
- 568.9M
- P/E TTM
- 21.2
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
| Line | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 53.4 | 137.4 | 43.0 | 38.5 | 31.6 | 194.5 | 81.7 | 108.4 | 60.0 | 85.3 | 63.1 | 76.2 | 84.6 | 69.2 | 29.6 | 36.5 | |
| Short-term investments | — | — | 40.9 | 102.8 | 184.3 | 35.0 | — | 57.0 | 51.6 | 8.1 | 19.0 | 4.9 | 11.4 | 31.7 | 67.9 | 57.4 | |
| Receivables | — | — | — | — | — | — | 9.7 | 20.8 | 28.9 | 25.5 | 32.5 | 40.4 | 47.8 | 32.0 | 53.7 | 34.1 | |
| Inventory | — | — | — | — | — | — | 2.0 | 2.6 | 3.2 | 3.5 | 7.1 | 4.5 | 7.1 | 8.7 | 5.5 | 13.3 | |
| Current assets | 53.7 | 149.0 | 96.4 | 149.4 | 223.5 | 236.5 | 106.4 | 203.0 | 166.3 | 146.1 | 140.0 | 134.3 | 156.2 | 147.7 | 162.7 | 145.1 | |
| Total assets | 55.4 | 151.7 | 104.4 | 162.8 | 239.8 | 252.8 | 165.5 | 259.1 | 234.9 | 244.2 | 226.6 | 222.1 | 230.5 | 213.3 | 216.3 | 192.7 | |
| Current liabilities | 0.6 | 21.7 | 19.3 | 44.4 | 32.4 | 37.5 | 58.3 | 67.1 | 90.8 | 114.3 | 109.6 | 77.5 | 99.4 | 96.1 | 81.3 | 49.8 | |
| Long-term debt | — | — | — | — | — | — | 48.5 | 151.9 | 95.0 | 84.0 | 102.0 | 98.3 | 65.7 | 21.7 | 0.0 | 0.0 | |
| Short-term debt | — | — | — | — | — | — | — | — | — | 14.3 | 0.0 | 0.0 | 34.0 | 45.3 | 22.5 | 0.0 | |
| Total liabilities | 1.0 | 22.8 | 20.4 | 45.7 | 33.8 | 43.0 | 112.2 | 224.8 | 217.4 | 250.2 | 229.0 | 200.5 | 177.1 | 121.2 | 86.0 | 54.2 | |
| Shareholders' equity | 54.4 | 128.9 | 84.0 | 117.0 | 206.0 | 209.8 | 53.3 | 34.3 | 17.5 | -6.0 | -2.4 | 21.6 | 53.4 | 92.1 | 130.3 | 138.5 |
USD millions · SEC XBRL
PUMA BIOTECHNOLOGY, INC. — questions
- How much cash does PUMA BIOTECHNOLOGY, INC. have?
- $36.5M in cash and cash equivalents as of 2026-06-30.
- How much debt does PUMA BIOTECHNOLOGY, INC. have?
- $0 of long-term debt and $0 due within a year as of 2026-06-30.
- What are PUMA BIOTECHNOLOGY, INC.'s total assets?
- $192.7M as of 2026-06-30.
- What is PUMA BIOTECHNOLOGY, INC.'s shareholders' equity?
- $138.5M as of 2026-06-30.
Every figure on this page comes from PUMA BIOTECHNOLOGY, INC.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.